Nanomedical Diagnostics’ Novel AGILE Graphene Biosensor Advances Kinase Research for the Development of Therapeutic Pharmaceuticals

Share Article

Study published in the Journal of the American Chemical Society demonstrates previously unattainable measurements for kinase drug discovery.

AGILE R100 Biosensor Chip Nanomedical Diagnostics

AGILE Biosensor Chip

The AGILE assay's ability to detail kinase mechanisms of action enables researchers to increase the speed of drug discovery.

Nanomedical Diagnostics, a biotech company developing and commercializing graphene biosensors for use in life science research and diagnostics, announces a breakthrough study published in the Journal of the American Chemical Society (Qvit 2016). The paper describes the use of AGILE R100, a novel label-free assay, to gain in vitro kinetic binding measurements between a peptide inhibitor and a kinase enzyme for the treatment of chronic heart disease. The measurements had not been able to be attained using traditional methods due to the instability of the protein kinase.

Kinases are rich targets for drug discovery but are notoriously difficult to study. “I needed quantitative validation that the kinase of interest was binding correctly,” says Dr. Nir Qvit, lead author of the study. “A traditional method such as SPR would have required fifty times more sample, with a high risk that the kinase would break down prior to completing the measurement. AGILE R100 provided successful in vitro kinetic binding data due the ability to measure kinetics within minutes of thawing our kinase, with a very small amount of sample. It was easy to use; we collected the data in one afternoon.”

AGILE R100 is a resistance-based assay built with graphene, a highly sensitive nanomaterial. The label-free, easy-to-use platform provides real-time quantitative analysis of biomolecular interactions including kinetics, affinity, and concentration with just 10 µL of sample per measurement. It excels in evaluating unstable kinases due to the fast total time to measurement.

“The instability of our sample had presented a challenge for us,” continued Dr. Qvit. “AGILE performed splendidly, and the data was quantitative and reproducible. The technology is one-of-a-kind.”

Kinases are a key target class for pharmaceutical development, and the need to measure these unstable enzymes quickly and easily is imperative. “AGILE’s ability to detail kinase mechanisms of action enables researchers to increase the speed of their therapy development, opening a world of possibility for kinase drug discovery,” says Nanomedical Diagnostics’ CEO, Ross Bundy. “Unlike other novel, cutting-edge assays, AGILE R100 is developed and available for large-scale use now.”

AGILE R100 is available for commercial sale, for research use only. For more information about Nanomedical Diagnostics or AGILE R100, visit http://www.nanomedicaldiagnostics.com.

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a biotech company based in San Diego, CA. Founded in late 2013, Nanomed has developed a breakthrough resistance-based assay that provides real-time, label-free kinetic binding and concentration data. The AGILE technology at the heart of the assay leverages graphene, a highly sensitive nanomaterial, to link biology directly with electronics for the first time, delivering the unique ability to sense in complex media such as tissue lysate and blood fractions, and use unprecedentedly small amounts of sample material.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Angela Shue
Visit website